Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy
Aim To determine the prevalence and to identify the risk factors of chloroquine maculopathy (CM), and to evaluate the association of plasma chloroquine (CQ) and desethylchloroquine (DCQ) levels and CM. Methods Rheumatoid arthritis (RA) patients who had taken CQ for at least 6 months and stable CQ do...
Gespeichert in:
| Veröffentlicht in: | International journal of rheumatic diseases 2013-02, Vol.16 (1), p.47-55 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 47 |
| container_title | International journal of rheumatic diseases |
| container_volume | 16 |
| creator | Chiowchanwisawakit, Praveena Nilganuwong, Surasak Srinonprasert, Varalak Boonprasert, Rasada Chandranipapongse, Weerawadee Chatsiricharoenkul, Somruedee Katchamart, Wanruchada Pongnarin, Piyapat Danwiriyakul, Wimonrat Koolvisoot, Ajchara Arromdee, Emvalee Ruangvaravate, Ngamkae |
| description | Aim
To determine the prevalence and to identify the risk factors of chloroquine maculopathy (CM), and to evaluate the association of plasma chloroquine (CQ) and desethylchloroquine (DCQ) levels and CM.
Methods
Rheumatoid arthritis (RA) patients who had taken CQ for at least 6 months and stable CQ dosage for at least 2 months were included. CM was diagnosed by dilated ocular examination and automated visual field. Plasma CQ and DCQ levels were determined by liquid chromatography tandem mass spectrometry method. Logistic regression was used to explore risk factors associated with CM.
Results
One hundred and ninety‐three patients were included with median CQ duration (range) of 50.2 months (6.0–269.8) and cumulative dose of 137.4 g (16.4–1226.5). The prevalence of CM was 13.5%. Factors associated with CM identified from univariate analysis were age > 60 years, and creatinine clearance with odds ratio (OR) (95%CI) of 5.79 (2.42, 13.84), and 0.98 (0.96, 1.00). In multivariate analysis, older age, usage > 5 years, and current dose from 2.5 mg/kg ideal body weight [IBW]/day were the factors significantly associated with CM with OR of 5.89 (2.38, 14.57), 2.94 (1.10, 7.83), and 3.32 (1.04, 10.60), respectively, while plasma CQ and DCQ showed no association with CM.
Conclusions
The prevalence of CM was 13.5% among RA patients taking CQ for at least 6 months. Age > 60 years, duration of CQ usage > 5 years and current CQ dose ≥2.5 mg/kg IBW/day were the risk factors for CM. The plasma CQ or DCQ levels demonstrated no correlation in developing CM. |
| doi_str_mv | 10.1111/1756-185X.12029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1317467733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2920112921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4099-87dc3e160222e11d71554afe32f9128e18a88ce8a794705df814cf638b7d78543</originalsourceid><addsrcrecordid>eNqFkU9PFTEUxRujEUTX7kwT1wO9_TPtLAkRJHlRFhjZNaVzK4V507Gdh77P4xdlxoEXXRi7aXP7O-c0PYS8BXYI0zoCreoKjLo6BM5484zs7ybPd2cJe-RVKbeM1SBq_ZLscSElaM33ya-LjPeuw94jdX1Lcyx3NDg_plxoSJn6my7l9H0Te6Rr5zddGtx4s13g1CFNgQ6dK2v3Fzpft1hwQrs_5z5NSf2Y3RhTX2js6ZCxjX6M_bd_Zb0mL4LrCr553A_Il9MPlycfq9Xns_OT41XlJWuayujWC4Sacc4RoNWglHQBBQ8NcINgnDEejdON1Ey1wYD0oRbmWrfaKCkOyPvFd5gfgWW0t2mT-ynSggAta62FmKijhfI5lZIx2CHHtctbC8zOpdj52-1cgf1dyqR49-i7uV5ju-OfWpgAtQA_Yofb__nZ44vVk3G16GIZ8edO5_KdrbXQyn79dGYvT69EI5myRjwAACyqGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1317467733</pqid></control><display><type>article</type><title>Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Chiowchanwisawakit, Praveena ; Nilganuwong, Surasak ; Srinonprasert, Varalak ; Boonprasert, Rasada ; Chandranipapongse, Weerawadee ; Chatsiricharoenkul, Somruedee ; Katchamart, Wanruchada ; Pongnarin, Piyapat ; Danwiriyakul, Wimonrat ; Koolvisoot, Ajchara ; Arromdee, Emvalee ; Ruangvaravate, Ngamkae</creator><creatorcontrib>Chiowchanwisawakit, Praveena ; Nilganuwong, Surasak ; Srinonprasert, Varalak ; Boonprasert, Rasada ; Chandranipapongse, Weerawadee ; Chatsiricharoenkul, Somruedee ; Katchamart, Wanruchada ; Pongnarin, Piyapat ; Danwiriyakul, Wimonrat ; Koolvisoot, Ajchara ; Arromdee, Emvalee ; Ruangvaravate, Ngamkae</creatorcontrib><description>Aim
To determine the prevalence and to identify the risk factors of chloroquine maculopathy (CM), and to evaluate the association of plasma chloroquine (CQ) and desethylchloroquine (DCQ) levels and CM.
Methods
Rheumatoid arthritis (RA) patients who had taken CQ for at least 6 months and stable CQ dosage for at least 2 months were included. CM was diagnosed by dilated ocular examination and automated visual field. Plasma CQ and DCQ levels were determined by liquid chromatography tandem mass spectrometry method. Logistic regression was used to explore risk factors associated with CM.
Results
One hundred and ninety‐three patients were included with median CQ duration (range) of 50.2 months (6.0–269.8) and cumulative dose of 137.4 g (16.4–1226.5). The prevalence of CM was 13.5%. Factors associated with CM identified from univariate analysis were age > 60 years, and creatinine clearance with odds ratio (OR) (95%CI) of 5.79 (2.42, 13.84), and 0.98 (0.96, 1.00). In multivariate analysis, older age, usage > 5 years, and current dose from 2.5 mg/kg ideal body weight [IBW]/day were the factors significantly associated with CM with OR of 5.89 (2.38, 14.57), 2.94 (1.10, 7.83), and 3.32 (1.04, 10.60), respectively, while plasma CQ and DCQ showed no association with CM.
Conclusions
The prevalence of CM was 13.5% among RA patients taking CQ for at least 6 months. Age > 60 years, duration of CQ usage > 5 years and current CQ dose ≥2.5 mg/kg IBW/day were the risk factors for CM. The plasma CQ or DCQ levels demonstrated no correlation in developing CM.</description><identifier>ISSN: 1756-1841</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/1756-185X.12029</identifier><identifier>PMID: 23441772</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>antimalarial drug ; Antirheumatic Agents - adverse effects ; Chloroquine - adverse effects ; Chloroquine - analogs & derivatives ; Chloroquine - blood ; chloroquine maculopathy ; Chromatography, High Pressure Liquid ; Cross-Sectional Studies ; Female ; Humans ; Humphrey visual field ; Male ; Middle Aged ; Multivariate analysis ; Plasma ; plasma chloroquine levels ; plasma desethylchloroquine levels ; Prevalence ; Retinal Diseases - chemically induced ; Retinal Diseases - epidemiology ; Retinal Diseases - pathology ; Risk Factors ; Tandem Mass Spectrometry ; Thailand - epidemiology</subject><ispartof>International journal of rheumatic diseases, 2013-02, Vol.16 (1), p.47-55</ispartof><rights>2013 The Authors International Journal of Rheumatic Diseases © 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd</rights><rights>2013 The Authors International Journal of Rheumatic Diseases © 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.</rights><rights>2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4099-87dc3e160222e11d71554afe32f9128e18a88ce8a794705df814cf638b7d78543</citedby><cites>FETCH-LOGICAL-c4099-87dc3e160222e11d71554afe32f9128e18a88ce8a794705df814cf638b7d78543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1756-185X.12029$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1756-185X.12029$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23441772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiowchanwisawakit, Praveena</creatorcontrib><creatorcontrib>Nilganuwong, Surasak</creatorcontrib><creatorcontrib>Srinonprasert, Varalak</creatorcontrib><creatorcontrib>Boonprasert, Rasada</creatorcontrib><creatorcontrib>Chandranipapongse, Weerawadee</creatorcontrib><creatorcontrib>Chatsiricharoenkul, Somruedee</creatorcontrib><creatorcontrib>Katchamart, Wanruchada</creatorcontrib><creatorcontrib>Pongnarin, Piyapat</creatorcontrib><creatorcontrib>Danwiriyakul, Wimonrat</creatorcontrib><creatorcontrib>Koolvisoot, Ajchara</creatorcontrib><creatorcontrib>Arromdee, Emvalee</creatorcontrib><creatorcontrib>Ruangvaravate, Ngamkae</creatorcontrib><title>Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><description>Aim
To determine the prevalence and to identify the risk factors of chloroquine maculopathy (CM), and to evaluate the association of plasma chloroquine (CQ) and desethylchloroquine (DCQ) levels and CM.
Methods
Rheumatoid arthritis (RA) patients who had taken CQ for at least 6 months and stable CQ dosage for at least 2 months were included. CM was diagnosed by dilated ocular examination and automated visual field. Plasma CQ and DCQ levels were determined by liquid chromatography tandem mass spectrometry method. Logistic regression was used to explore risk factors associated with CM.
Results
One hundred and ninety‐three patients were included with median CQ duration (range) of 50.2 months (6.0–269.8) and cumulative dose of 137.4 g (16.4–1226.5). The prevalence of CM was 13.5%. Factors associated with CM identified from univariate analysis were age > 60 years, and creatinine clearance with odds ratio (OR) (95%CI) of 5.79 (2.42, 13.84), and 0.98 (0.96, 1.00). In multivariate analysis, older age, usage > 5 years, and current dose from 2.5 mg/kg ideal body weight [IBW]/day were the factors significantly associated with CM with OR of 5.89 (2.38, 14.57), 2.94 (1.10, 7.83), and 3.32 (1.04, 10.60), respectively, while plasma CQ and DCQ showed no association with CM.
Conclusions
The prevalence of CM was 13.5% among RA patients taking CQ for at least 6 months. Age > 60 years, duration of CQ usage > 5 years and current CQ dose ≥2.5 mg/kg IBW/day were the risk factors for CM. The plasma CQ or DCQ levels demonstrated no correlation in developing CM.</description><subject>antimalarial drug</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Chloroquine - adverse effects</subject><subject>Chloroquine - analogs & derivatives</subject><subject>Chloroquine - blood</subject><subject>chloroquine maculopathy</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Humphrey visual field</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Plasma</subject><subject>plasma chloroquine levels</subject><subject>plasma desethylchloroquine levels</subject><subject>Prevalence</subject><subject>Retinal Diseases - chemically induced</subject><subject>Retinal Diseases - epidemiology</subject><subject>Retinal Diseases - pathology</subject><subject>Risk Factors</subject><subject>Tandem Mass Spectrometry</subject><subject>Thailand - epidemiology</subject><issn>1756-1841</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9PFTEUxRujEUTX7kwT1wO9_TPtLAkRJHlRFhjZNaVzK4V507Gdh77P4xdlxoEXXRi7aXP7O-c0PYS8BXYI0zoCreoKjLo6BM5484zs7ybPd2cJe-RVKbeM1SBq_ZLscSElaM33ya-LjPeuw94jdX1Lcyx3NDg_plxoSJn6my7l9H0Te6Rr5zddGtx4s13g1CFNgQ6dK2v3Fzpft1hwQrs_5z5NSf2Y3RhTX2js6ZCxjX6M_bd_Zb0mL4LrCr553A_Il9MPlycfq9Xns_OT41XlJWuayujWC4Sacc4RoNWglHQBBQ8NcINgnDEejdON1Ey1wYD0oRbmWrfaKCkOyPvFd5gfgWW0t2mT-ynSggAta62FmKijhfI5lZIx2CHHtctbC8zOpdj52-1cgf1dyqR49-i7uV5ju-OfWpgAtQA_Yofb__nZ44vVk3G16GIZ8edO5_KdrbXQyn79dGYvT69EI5myRjwAACyqGw</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Chiowchanwisawakit, Praveena</creator><creator>Nilganuwong, Surasak</creator><creator>Srinonprasert, Varalak</creator><creator>Boonprasert, Rasada</creator><creator>Chandranipapongse, Weerawadee</creator><creator>Chatsiricharoenkul, Somruedee</creator><creator>Katchamart, Wanruchada</creator><creator>Pongnarin, Piyapat</creator><creator>Danwiriyakul, Wimonrat</creator><creator>Koolvisoot, Ajchara</creator><creator>Arromdee, Emvalee</creator><creator>Ruangvaravate, Ngamkae</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201302</creationdate><title>Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy</title><author>Chiowchanwisawakit, Praveena ; Nilganuwong, Surasak ; Srinonprasert, Varalak ; Boonprasert, Rasada ; Chandranipapongse, Weerawadee ; Chatsiricharoenkul, Somruedee ; Katchamart, Wanruchada ; Pongnarin, Piyapat ; Danwiriyakul, Wimonrat ; Koolvisoot, Ajchara ; Arromdee, Emvalee ; Ruangvaravate, Ngamkae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4099-87dc3e160222e11d71554afe32f9128e18a88ce8a794705df814cf638b7d78543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>antimalarial drug</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Chloroquine - adverse effects</topic><topic>Chloroquine - analogs & derivatives</topic><topic>Chloroquine - blood</topic><topic>chloroquine maculopathy</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Humphrey visual field</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Plasma</topic><topic>plasma chloroquine levels</topic><topic>plasma desethylchloroquine levels</topic><topic>Prevalence</topic><topic>Retinal Diseases - chemically induced</topic><topic>Retinal Diseases - epidemiology</topic><topic>Retinal Diseases - pathology</topic><topic>Risk Factors</topic><topic>Tandem Mass Spectrometry</topic><topic>Thailand - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiowchanwisawakit, Praveena</creatorcontrib><creatorcontrib>Nilganuwong, Surasak</creatorcontrib><creatorcontrib>Srinonprasert, Varalak</creatorcontrib><creatorcontrib>Boonprasert, Rasada</creatorcontrib><creatorcontrib>Chandranipapongse, Weerawadee</creatorcontrib><creatorcontrib>Chatsiricharoenkul, Somruedee</creatorcontrib><creatorcontrib>Katchamart, Wanruchada</creatorcontrib><creatorcontrib>Pongnarin, Piyapat</creatorcontrib><creatorcontrib>Danwiriyakul, Wimonrat</creatorcontrib><creatorcontrib>Koolvisoot, Ajchara</creatorcontrib><creatorcontrib>Arromdee, Emvalee</creatorcontrib><creatorcontrib>Ruangvaravate, Ngamkae</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiowchanwisawakit, Praveena</au><au>Nilganuwong, Surasak</au><au>Srinonprasert, Varalak</au><au>Boonprasert, Rasada</au><au>Chandranipapongse, Weerawadee</au><au>Chatsiricharoenkul, Somruedee</au><au>Katchamart, Wanruchada</au><au>Pongnarin, Piyapat</au><au>Danwiriyakul, Wimonrat</au><au>Koolvisoot, Ajchara</au><au>Arromdee, Emvalee</au><au>Ruangvaravate, Ngamkae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2013-02</date><risdate>2013</risdate><volume>16</volume><issue>1</issue><spage>47</spage><epage>55</epage><pages>47-55</pages><issn>1756-1841</issn><eissn>1756-185X</eissn><abstract>Aim
To determine the prevalence and to identify the risk factors of chloroquine maculopathy (CM), and to evaluate the association of plasma chloroquine (CQ) and desethylchloroquine (DCQ) levels and CM.
Methods
Rheumatoid arthritis (RA) patients who had taken CQ for at least 6 months and stable CQ dosage for at least 2 months were included. CM was diagnosed by dilated ocular examination and automated visual field. Plasma CQ and DCQ levels were determined by liquid chromatography tandem mass spectrometry method. Logistic regression was used to explore risk factors associated with CM.
Results
One hundred and ninety‐three patients were included with median CQ duration (range) of 50.2 months (6.0–269.8) and cumulative dose of 137.4 g (16.4–1226.5). The prevalence of CM was 13.5%. Factors associated with CM identified from univariate analysis were age > 60 years, and creatinine clearance with odds ratio (OR) (95%CI) of 5.79 (2.42, 13.84), and 0.98 (0.96, 1.00). In multivariate analysis, older age, usage > 5 years, and current dose from 2.5 mg/kg ideal body weight [IBW]/day were the factors significantly associated with CM with OR of 5.89 (2.38, 14.57), 2.94 (1.10, 7.83), and 3.32 (1.04, 10.60), respectively, while plasma CQ and DCQ showed no association with CM.
Conclusions
The prevalence of CM was 13.5% among RA patients taking CQ for at least 6 months. Age > 60 years, duration of CQ usage > 5 years and current CQ dose ≥2.5 mg/kg IBW/day were the risk factors for CM. The plasma CQ or DCQ levels demonstrated no correlation in developing CM.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>23441772</pmid><doi>10.1111/1756-185X.12029</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-1841 |
| ispartof | International journal of rheumatic diseases, 2013-02, Vol.16 (1), p.47-55 |
| issn | 1756-1841 1756-185X |
| language | eng |
| recordid | cdi_proquest_journals_1317467733 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | antimalarial drug Antirheumatic Agents - adverse effects Chloroquine - adverse effects Chloroquine - analogs & derivatives Chloroquine - blood chloroquine maculopathy Chromatography, High Pressure Liquid Cross-Sectional Studies Female Humans Humphrey visual field Male Middle Aged Multivariate analysis Plasma plasma chloroquine levels plasma desethylchloroquine levels Prevalence Retinal Diseases - chemically induced Retinal Diseases - epidemiology Retinal Diseases - pathology Risk Factors Tandem Mass Spectrometry Thailand - epidemiology |
| title | Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T18%3A47%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20risk%20factors%20for%20chloroquine%20maculopathy%20and%20role%20of%20plasma%20chloroquine%20and%20desethylchloroquine%20concentrations%20in%20predicting%20chloroquine%20maculopathy&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=Chiowchanwisawakit,%20Praveena&rft.date=2013-02&rft.volume=16&rft.issue=1&rft.spage=47&rft.epage=55&rft.pages=47-55&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/1756-185X.12029&rft_dat=%3Cproquest_cross%3E2920112921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1317467733&rft_id=info:pmid/23441772&rfr_iscdi=true |